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Abstract  
 
Neonatal livers are a potential source of good quality hepatocytes for clinical transplantation. We 
compared viability and function of neonatal and adult hepatocytes, and report their clinical use both 
intra-portally and in alginate microbeads. Following isolation from donor livers, hepatocyte function 
was assessed using albumin, alpha-1 antitrypsin and factor VII. Metabolic function was investigated 
by measuring resorufin conjugation, ammonia metabolism, UGT enzyme activity and cytochrome 
P450 function following induction.  Activation of the instant blood meditated inflammatory (IBMIR) 
reaction by neonatal and adult hepatocytes was investigated using an in vitro blood perfusion model 
and tissue factor expression was analysed using qPCR. Clinical hepatocyte transplantation was 
undertaken using standard protocols. Hepatocytes were isolated from 14 neonatal livers, with an 
average viability of 89.4±1.8% (Mean±SEM) and average yield of 9.3x106±2.0x106cells/g. 
Hepatocytes were isolated from 14 adult livers with an average viability of 78.0±2.4% and yield 
2.2x106±0.5x105cells/g. Neonatal hepatocytes had significantly higher viability post cryopreservation 
than adult hepatocytes, with better attachment efficiency and less plasma membrane leakage. There 
were no differences in albumin, alpha-1 antitrypsin and factor VII synthesis between neonatal and 
adult hepatocytes (P>0.05). Neonatal cells had inducible phase I enzymes as assessed by cytochrome 
p450 function and functional phase II enzymes, in which activity was comparable to adult 
hepatocytes. In an in vitro blood perfusion model adult hepatocytes elicited increased thrombus 
formation with a greater consumption of platelets and white cells compared with neonatal hepatocytes  
(28.3x109vs118.7x109 and 3.34x109vs6.63x109,P<0.01). Intraportal transplantation and intraperitoneal 
transplantation of alginate encapsulated hepatocytes was safe and preliminary data suggest the cells 
may activate the immune response to a lesser degree than adult cells. Conclusion: We have shown 
neonatal hepatocytes have excellent cell viability, function and drug metabolism making them a 
suitable alternative source for clinical hepatocyte transplantation.  
   
 
 
Manuscript ID LT-17-446.R1 
 
 
Introduction  
Hepatocyte transplantation (HT) has demonstrated some promise as an alternative to liver 
transplantation (LT) for children with liver-based metabolic diseases and acute liver failure (ALF). 
Due to the shortage of donor organs, pediatric patients often face a long-wait for an appropriately 
sized organ of sufficient quality to become available. As a result, hepatocyte transplantation is being 
explored as an alternative. Significant improvement in metabolic function has been demonstrated 
following hepatocyte transplantation in children with liver-based metabolic disease, however efficacy 
beyond 18 months has yet to be shown.  
Human hepatocytes are isolated from whole donor livers or segments unsuitable for whole organ 
transplantation, using a collagenase perfusion technique and purified using centrifugation (1–3). For 
patients with liver-based metabolic diseases, the cells are administered under radiological guidance 
into the portal vein, from which they migrate across the sinusoidal endothelial barrier and engraft in 
the parenchyma. Successful engraftment depends on the ability of hepatocytes to survive the innate 
immune system and successfully transverse the sinusoids. Viability and function of transplanted 
hepatocytes is associated with the quality of liver tissue from which they are isolated.  In the case of 
children with ALF, administration of hepatocytes intra-portally is challenging, particularly in the 
coagulopathic, critically ill patient. As an alternative, microbeads of alginate encapsulated hepatocytes 
which are injected into the intraperitoneal cavity is a newly described approach, in which the semi-
permeable gel alginate allows the entry of oxygen and nutrients into the microbead while 
simultaneously protecting the hepatocytes against the immune system (4). One of the major 
limitations of the technique is that the cells are largely derived from poor quality livers that have 
otherwise been rejected for transplantation, thus the quality of the cells themselves is often very poor. 
Neonatal livers have recently been explored as a cell source for hepatocyte transplantation to 
overcome this major limitation. Neonatal livers are rarely used for solid organ transplantation due to 
the high incidence of hepatic artery thrombosis, which may result from decreased or absent protein C 
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synthesis by the donor liver (5). Instead they may be offered for hepatocyte isolation for the purpose 
of cell transplantation. Transplantation of human neonatal hepatocytes into a rat model of Crigler 
Najjar syndrome showed animals that received neonatal hepatocytes had significantly higher 
concentrations of UGT1A1 and conjugated bilirubin expression at both 3 days and 6 months 
compared to adult cells. Functionality of neonatal hepatocytes has also been shown in 4 patients with 
severe urea cycle disorders, showing metabolic stabilization for 4-13 months following 
transplantation (6,7). 
 In the UK, the introduction of new guidelines defining brain death in newborns has increased the 
number of donor organs that are offered for hepatocyte isolation, resulting in an increased 
requirement to characterize these cells in the context of hepatocyte transplantation (8). The aim of this 
study was to investigate whether neonatal hepatocytes are a suitable alternative to adult hepatocytes. 
To investigate this we compared viability, functionality, drug metabolism and pro-coagulant effects of 
these cells.  We also describe three cases in which hepatocyte transplantation was undertaken using 
neonatal cells.  
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Materials and Methods 
Ethical approval for the isolation of primary human hepatocytes was obtained from the National 
Research Ethics Service (King’s College Hospital LREC (LREC 01-016). The study protocol 
conformed to the ethical guidelines of the 1975 Declaration of Helsinki.  
Organs are donated through the National Health Service Blood and Transplant (NHSBT) and offered 
for hepatocyte transplantation following decline for solid organ transplantation with appropriate 
consent in place for clinical and research use.  
Neonatal Liver Procurement 
For donation after circulatory determination of death (DCDD), maximum warm ischemic time (WIT) 
was usually set at 90 minutes. In the absence of an alternative definition for neonatal WIT, the adult 
definition is used, which is the time from oxygen saturation of 70% or systolic pressure of 50mmHg 
(depending on which agonal observation occurs first), to aortic cannulation. DCDD and donation 
following neurological determination of death (DNDD) were accepted according to guidelines 
published by the RCPCH (8). The cold ischaemia time is defined as the time from aortic cannulation 
to hepatocyte isolation. For paediatric DCDD procurement, asystole was awaited after withdrawal of 
life support. Following declaration of death and a 5 min stand off period, a thoraco-abdominal 
incision was made, followed by abdominal aorta cannulation and cross clamp in the chest. Depending 
on vessel size, the portal vein (PV) was cannulated either in the hilum or via the small mesenteric vein 
in the root of the small bowel mesentery. In situ 500ml ice-cold University of Wisconsin Solution 
(UW) was perfused through the aorta and PV followed by rapid hepatectomy. A further 250-500ml of 
UW was perfused through the PV and hepatic artery until the effluent became clear. Cold static 
storage was the standard.  
Neonatal Hepatocyte Isolation  
Primary hepatocytes were isolated from whole livers as described by Mitry et al (9,10). Briefly, major 
blood vessels on the liver surface were cut, cannulated, and secured through suturing. The tissue was 
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perfused at a flow rate of 50ml/min with buffer (calcium-free HBSS, 1M HEPES and 0.5mM EGTA), 
followed by calcium-free HBSS and EMEM containing 0.05% collagenase (VitaCyte, Indianapolis, 
USA). Once digested, the tissue was minced and sieved. Hepatocytes were purified by washing three 
times in ice-cold EMEM and centrifuged at 50xg at 4°C for 5 minutes. Cells used were cryopreserved 
in UW solution with 5% glucose and 10% DMSO using a controlled rate freezer (Kryo 10, series III, 
Planer Products, Ltd, Middlesex, UK) and stored at -140°C.   
Thawing and culture of cryopreserved primary hepatocytes  
All assays were carried out using hepatocytes that had been cryopreserved and thawed. Cryopreserved 
hepatocytes were thawed at 37ºC, re-suspended in Williams E (WE) medium and centrifuged at 50xg 
for 5 minutes at 4ºC. Cells were re-suspended and viability determined using the trypan blue 
exclusion assay. Hepatocytes were cultured in WE containing; 50µg/ml heat-inactivated foetal bovine 
serum, 10mM HEPES, Penicillin (100U/ml)- Streptomycin (100µg/ml), Insulin(10mg/L)–
Transferrin(5.5mg/L)-Selenium(6.7µg/L),10-7M dexamethasone and 2mM L-glutamine. 96 well 
plates were coated with 0.1mg/ml rat-tail collagen type 1 overnight and washed with PBS.  
Assessment of hepatocyte viability, attachment and plasma membrane damage  
MTT assay  
Hepatocyte viability was determined using an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay. Briefly, cells were cultured for 24h at 37°C, 5% CO2, 
supernatant removed and cultured with serum-free medium containing 0.5mg/ml of MTT (Sigma 
Aldrich, Dorset, UK) for 4 hours. The produced formazan was dissolved in DMSO and the optical 
density read at 570nm on a Dynex MRX microplate reader (see supplementary information for more 
details).  
Sulphorhodamine B (SRB) assay 
A Sulphorhodamine B (SRB) assay was carried out to determine cell attachment. Hepatocytes were 
cultured for 24h at 37°C, 5% CO2. Supernatant was removed and replaced with 50% Trichloroacetic 
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acid (TCA), cells were washed and SRB added before solubilisation in 1% acetic acid. The optical 
density was read at 564nm on a Dynex MRX microplate reader (see supplementary information for 
more details).  
Lactate dehydrogenase assay  
Plasma membrane damage following cryopreservation was measured using a lactate dehydrogenase 
(LDH) assay (Pierce LDH cytotoxicity kit, Thermo Fisher Scientific, Paisley, UK.)   Cells were 
cultured for 24h at 37°C, 5% CO2. Sterile water was added to control cells, which represented 
spontaneous LDH activity. Lysis buffer was added to other wells, which represented maximum LDH 
activity. Reaction mixture was added and absorbance read at 490nm and 680nm (background signal). 
LDH activity was quantified as the percentage of spontaneous LDH activity over the maximum LDH 
activity (see supplementary information for more details).  
Immunofluorescent Staining  
For visualization of albumin expression cells were fixed with 4% PFA, permeabilised with 0.01% 
Triton X-100, blocked with PBS + 3% BSA and incubated with goat anti-human albumin antibody 
1:100 (Bethyl Laboratories, Inc, Texas, USA), followed by a goat anti-mouse 594 secondary antibody 
1:1000 (Invitrogen). For analysis of foetal markers, a mouse monoclonal EpCAM antibody 1:50 
(Santa Cruz, Heidelbery, Germany) and a mouse monoclonal alpha-1 fetoprotein (AFP), followed by 
a goat anti-mouse 488 secondary antibody 1:200 (Thermo Fisher Scientific, Paisley, UK) were used. 
Images were taken on an Inverted Microscope Leica DMi8 x20 magnification.  
Assessment of hepatocyte metabolic function  
Albumin, Alpha-1 Antitrypsin and Factor VII synthesis 
For functional assays, media was collected 12 hours post-plating and enzyme immunoasssays carried 
out for human Albumin (Bethyl Laboratories, Inc, Texas, USA), Alpha-1 Anti-trypsin (Bethyl 
Laboratories, Inc, Texas, USA) and  Factor VII (Assay Pro, Missouri, USA) according to the 
manufactures instructions (see supplementary information for more details). Values were normalized 
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to protein content using a Bicinchoninic Acid Assay (BCA) Protein Assay (see supplementary 
information). 
Ammonia Metabolism  
Urea synthesis was measured using a QuantiChrom™ Urea Assay kit (Universal Biologicals, 
Cambridge, UK). Cells were washed with PBS and treated with 5mM ammonium chloride (Sigma 
Aldrich, Dorset, UK) for 6 hours before measurement of urea synthesis (see supplementary 
information for more details).  
Phase II assay  
Phase II activity was measured by quantifying the conjugation of resorufin. Cells were cultured for 
24h at 37°C, 5% CO2. 10µg/ml of resorufin was added for 2 hours at 37°C, 5% CO2, Resorufin values 
were measured at 0hrs and 2hrs and the concentration of resorufin calculated using a standard curve 
(100ng/ml-1.56ng/ml). Values at 2hrs were subtracted from the 0hr time point to measure decrease of 
fluorescent resorufin due to its conjugation.  
UDP glucuronosyltransferase activity (UGT) activity  
UGT activity was measured using a UGT-Glo assay (Promega, Southampton, UK).Cells were 
cultured at 37°C, 5% CO2 for 24hrs. To measure UGT activity, cells were treated with or without 
50µM uridine 5’diphosphoglucuronic acid (UDPGA) and proluciferin substrates (50µM UGT 
multienzyme mix) for 1 hour at 37°C, 5% CO2). Following incubation, 50μl of detection agent was 
added to samples and the luminescence recorded immediately on FLUOstar Omega Microplate 
Reader (BMG Labtech, Ortenbery, Germany) from 0 to 20 minutes every 1 minute, integration time 1 
second.  Values shown are the cells without UDPGA minus the cells with UDPGA as a percentage of 
the cells without UDPGA.  
7-Ethoxyresorufin-O-Deethylase (EROD) assay  
Cytochrome P450-1A1/1A2 activity was assessed by measuring the conversion of 7-ethoxyresorufin 
to resorufin. Cells were cultured for 24h at 37°C, 5% CO2. Cells were treated with 20µM 7-
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ethoxyresorufin and 1.5mM salicylamide and the concentration of resorufin calculated using a 
standard curve (100ng/ml-1.56ng/ml).  
 
Cytochrome P450 assays  
Cytochrome P450-1A1, 1A2, 2C9, 3A4 and 3A7 activity were measured using a commercial 
P450-GloTM cell-based assay (Promega, Southampton, UK) according to manufactures instructions. 
Hepatocytes were cultured for 24h at 37°C, 5% CO2 and cytochrome p450 activity induced every day 
for 3 days before detection of cytochrome activity. CYP1A1/1A2 activity was induced using 50µM 
omeprazole (OMP), CYP2C9 and CYP2B6 activity was induced using 1mM phenobarbital (PHE) and 
CYP3A4 and CYP3A7 activity was induced using 25µM rifampicin (RIF). Following 3 days of 
induction, 50μl of luciferin substrate added/well (Luciferin-CEE/CYP1A1 1:50, Luciferin-
ME/CYP1A2 1:50, Luciferin-H/CYP2C9 1:50, Luciferin-IPA/CYP3A4 1:1000, Luciferin-
CEE/CYP3A7 1:50). Cells were incubated with the luciferin substrate for 60 minutes (CYP3A4) and 
3 hours (CYP1A1, 1A2, 3A4 and 3A7). Following incubation, 50μl of detection agent was added to 
samples and the luminescence recorded immediately on FLUOstar Omega Microplate Reader (BMG 
Labtech, Ortenbery, Germany) from 0 to 20 minutes every 1 minute, integration time 1 second.  
Values were normalised to DNA content using Quant-IT Picogreen® (Thermo Fisher Scientific, 
Paisley, UK) (see supplementary information for more details).  
Chandler loop model  
A Chandler loop model was designed based on previous reports (11,12). Briefly, custom-made 
clinical grade polyvinyl chloride (PVC) tubing (3/16”x1x16”x40cm) coated in heparin using end 
point attached heparin technology (Medtronic Carmeda® Bioactive surface, Watford, UK) was filled 
with 6mls ABO matched blood containing the relevant samples and closed into circuits with heparin 
coated 3/16” polystyrene connectors. Tubing loops were rotated at 24rpm and incubated at 37°C for 0, 
15, 30 and 60 minutes. Samples were taken with a Pasteur pipette into 1ml EDTA tubes (1.8mg 
EDTA per milliliter of blood).  
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Whole blood samples were immediately analysed for full blood counts on an ADIVA 2120 
haematology system (Siemens Healthcare Diagnostics, Surrey, UK). The remaining samples were 
centrifuged at 2000xg for 15 minutes to obtain the plasma. Samples were stored at -80°C until 
analysis. 
Cytokine expression was analysed using a high sensitivity Randox HS X Biochip Array designed to 
measure 12 cytokines/chemokines (IL-2, IL-4, IL-6, IL-8, IL-10, VEGF, IFN-γ, TNF-α, Il-1a, IL-1b, 
MCP-1 (Randox Laboratories Ltd, County Antrim, UK). . 
Tissue Factor Expression  
mRNA  
RNA was extracted from neonatal and adult cells using a miRNeasy kit (Qiagen, Manchester, UK). 
qPCR for TF and β-actin was carried using Taqman® probes (F3 gene, Assay ID Hs1076029_m1, Lot 
#P150911-007 B12 and β-actin, Assay ID Hs9999903_m1 Lot # P150213_011 A09, Thermo Fisher 
Scientific, Paisley, UK). RNA was converted to cDNA the Omniscript Reverse Transcriptase kit 
(Qiagen, Manchester, UK). The PCR program was 95°C for 15 minutes, 40 cycles of 94°C for 15 
seconds and 57°C for 30 seconds, and was run on the Applied Biosystems QuantStudio 7 Flex Real 
Time PCR system (Thermo Fisher Scientific, Paisley, UK). Results were normalised to β-actin and 
the comparative CT method used to analyse the results.  
Protein expression  
For analysis of tissue factor expression, hepatocytes were plated in 4 well chamber slides at 250,000 
cells/chamber and incubated at 37ºC, 5% CO2 overnight. Slides were prepared for staining as 
described in Materials and Methods (2.8.1). Sections were stained with a primary rabbit monoclonal 
tissue factor antibody (Abcam, Cambridge, UK) at a 1:50 dilution for 1 hour at RT, followed by a 
donkey anti-rabbit ALexa-Fluor 488 secondary antibody (Thermo Fisher Scientific, Paisley, UK) at a 
1:200 dilution. 
 
Clinical Hepatocyte Transplantation 
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A national hepatocyte transplantation programme is in operation at King’s College Hospital, London. 
Children are referred for either intraportal infusion of hepatocytes for liver-based metabolic disease or 
for intraperitoneal infusion of alginate encapsulated hepatocytes for ALF. Hepatocytes may be used 
either fresh, or cryopreserved. Hepatocytes must meet minimum viability and microbiological criteria 
prior to clinical cell transplantation. 
 For liver-based metabolic disease, radiologically guided intraportal infusion of hepatocytes is 
undertaken via the umbilical vein if patent and the ductus venosus is closed or accessed surgically via 
the inferior mesenteric vein at laparotomy. Cells are infused while measuring portal pressure. 
Standard immunosuppression is with corticosteroids, basiliximab and tacrolimus. Prophylactic broad 
spectrum antibiotics are used for 48 hours.  
Children with ALF who meet criteria for LT may be candidates for hepatocyte transplantation in the 
form of alginate microbead infusion. Microbeads are formed of hepatocytes encapsulated in sterile-
alginate (Novamatrix) using an Encapsulator B-390 (Buchi) forming microbeads of approximately 
500µM in size.  These microbeads are infused into the intraperitoneal cavity via a wide bore cannula 
under ultrasound guidance. No immunosuppression is required as alginate is bio-inert and shields the 
hepatocyte from the immune system. Antibiotic prophylaxis as before is given. After full recovery 
(usually one month), or at time of liver transplant, the microbeads are removed using a laparoscopic 
peritoneal lavage.  
 
Statistical Analysis  
Data were analysed using GraphPad Prism V5 (GraphPad Software La Jolla, CA). Normality was 
tested for using the Kolgrov-Smirnov normality test. For normally distributed data (MTT, viability at 
isolation, viability post-thawing and yield), data were evaluated using a two-tailed unpaired t-test. For 
non-parametric data (SRB, albumin and urea), data were analysed using the Mann-Whitney U test. In 
Chandler loop samples and clinical data, sample size was not sufficient for appropriate statistical tests. 
All data are expressed as mean ± SEM. All data were analysed using GraphPad Prism V5 (GraphPad 
Software La Jolla, CA).  
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Results  
Viability and Yield  
Hepatocytes were isolated from 14 neonatal livers (Table 1; Figure 1; 3 DNDD, 11 DCDD), with an 
average viability of 89.4±1.8% and average yield of 9.3x106±2.0x106cells/g. For comparison, 
hepatocytes were isolated from 14 adult livers (aged >16 years), with an average viability of 
78.6±2.4% and average yield 2.2x106±0.5x105cells/g (Figure 1A and 1B). Adult hepatocytes used as 
controls were taken from the latest 14 isolations in order to accurately represent the quality of cells 
that result from livers currently offered to the programme and to avoid era bias. Following 
cryopreservation and thawing, mean viability of neonatal hepatocytes was significantly higher 
compared to adult hepatocytes (Figure 1C, 77.6±3.6% vs 59.2±2.5% N=9, P<0.001). MTT assay after 
cell plating demonstrated neonatal hepatocytes had significantly higher viability than adult 
hepatocytes (Figure 1D; OD; 1.0±0.2 vs 0.4±0.1, P<0.05). A lactate dehydrogenase (LDH) assay was 
used to measure plasma membrane damage of cryopreserved hepatocytes. Adult hepatocytes had 
significantly higher LDH leakage following cryopreservation and thawing compared to neonatal 
hepatocytes (Figure 1E; 70.7±10.5% vs 43.4±5.2%, P<0.05).  
Cell Morphology and Attachment Efficiency 
An SRB attachment assay showed cryopreserved neonatal hepatocytes had significantly higher 
attachment efficiency than adult hepatocytes (Figures 1F-1G: O.D, 2.4±0.3 vs 0.6±0.03, P<0.01). 
Images demonstrate neonatal hepatocytes formed complete monolayers on collagen-coated plates 24 
hours post-plating, whereas adult hepatocytes are rounded with low confluence.  
Hepatocyte Function  
There was no significant difference in the production of liver specific proteins; albumin, alpha-1 
antitrypsin and factor VII synthesis between neonatal and adult hepatocytes at 1-day post plating 
(Figure 2A-C; Albumin - 95.3±33 vs 59.5±18.1ng/µg of cell protein/24h, N=8, P>0.05, AAT – 
122.5±17.1 vs 91.1±15.3ng/µg of cell protein/24h, N=6, P>0.05 and factor VII 3.0±0.65 vs 6.78±3.4 
ng/µg of cell protein/24h, N=3 P>0.05  ). Ammonia metabolism was comparable between neonatal 
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and adult cells as assessed by a ureagenesis assay (Figure 2D; 1.1±0.3 µg/hr/µg of protein vs 0.6±0.4 
µg/hr/µg of protein, N=5, P>0.05). Phase II enzyme activity of neonatal and adult hepatocytes was 
compared by measuring resorufin conjugation. Neonatal hepatocytes had greater resorufin 
conjugation than adult hepatocytes, although this was not significant (Figure 2E; 531.8±223.5pg/hr vs 
97.4±51.0pg/hr, N=3, P>0.05). Phase II enzyme function was further assessed by measuring activity 
of UDP glucuronosyltransferase (UGT) enzymes. Incubation with uridine 5’diphosphoglucuronic acid 
(UDPGA) and proluciferin UGT multi-enzyme substrates showed neonatal function of UGT enzymes 
was comparable to adult hepatocytes (Figure 2F; 30.0±7.2 vs 37.7±4.0 % UGT substrate consumed, 
N=3, P>0.05).   
Drug Metabolism of neonatal hepatocytes 
To determine the ability of neonatal hepatocytes to metabolize drug compounds, different cytochrome 
p450 isoforms were investigated following a 3-day induction. 3 out of 5 neonatal batches tested 
showed increased cytochrome p450 activity following induction with omeprazole (CYP1A2) and 
phenobarbital (CYP2C9 and CYP2B6) (Figure 3; Table 2 see supplementary information). Four out 
of five batches of neonatal hepatocytes showed increased activity of CYP3A4 and CYP3A7 following 
induction with rifampicin (Figure 3, Table 2 see supplementary information). These results are 
comparable to adult hepatocytes, which are not all inducible following the isolation and 
cryopreservation process (data not shown).  
Phase I activity was further investigated by measuring the conversion of 7-ethoxyresorufin to 
resorufin. CYP1A1/1A2 of neonatal hepatocytes was comparable to that of adult hepatocytes 
following induction with omeprazole for 3 days (Figure 2; 1.9±0.1 vs 3.3±0.3 of resorufin 
formed/minute/million cells).   
Neonatal hepatocytes and effect on thrombus formation in vitro  
An in vitro tubing loop model (Chandler loop) was used to compare how neonatal and adult 
hepatocytes trigger activation of the coagulation cascade when in contact with ABO-matched blood 
(13,14). Adult hepatocytes elicited a visible thrombus formation and a drop in platelet count after 60 
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minutes compared to neonatal hepatocytes and control blood only samples (no clot formation) (Figure 
4a; 28.3 x109 (AH) vs 118.7 x109 (NH) vs  214.3x109 cell/L, N=3). Furthermore, after 60 minutes 
adult hepatocytes caused a decrease in circulating white cells compared to neonatal cells (Figure 4b; 
3.34 x109 vs 6.63 x109 vs 5.8 x109, N=3). There was no difference between neonatal and adult 
hepatocytes in the expression of the complement protein C5b-9. These preliminary results suggest 
neonatal hepatocytes may not trigger coagulation activation and platelet/white cell consumption to the 
same extent as adult hepatocytes. To investigate the potential mechanisms of IBMIR activation by 
neonatal hepatocytes, tissue factor expression was quantified. Immunofluorescent staining showed 
adult hepatocytes had strong expression of tissue factor in the cytosol. Tissue factor expression was 
absent in hepatocytes derived from neonatal hepatocytes (Figure 4d). This was further confirmed by 
qPCR analysis for the tissue factor gene. This showed that adult hepatocytes had significantly higher 
tissue factor expression than neonatal hepatocytes (Figure 4e, relative expression 2.06±0.16 vs 
0.32±0.14, N=5, P<0.001). Cytokine analysis showed there were no differences in IL-2, IL-6, IL-8, 
VEGF, TNF-a, IL-1a, MCP-1, EGF and IL1-RA, although neonatal hepatocytes did show a trend 
towards higher IL-10 production (see supplementary information) 
Clinical use of Neonatal Hepatocytes  
Three children have undergone transplantation of neonatal hepatocytes in our center to date. Two of 
these children underwent the procedure for ALF and received cryopreserved neonatal hepatocytes 
encapsulated in alginate microbeads injected into the intraperitoneal cavity while awaiting liver 
transplantation. One child with a rare inborn error of sulphite metabolism received cryopreserved 
neonatal hepatocytes via the intraportal route.  
Child 1 and 2 with acute liver failure were aged 24 and 18 months respectively at time of hepatocyte 
transplantation. Child 1 was born prematurely and diagnosed with ALF due to neonatal 
hemochromatosis liver disease (siderosis on salivary gland biopsy) with persistent and worsening 
liver function despite treatment with exchange transfusion and intravenous immunoglobulin. She was 
listed for liver transplantation but due to her small size an organ was not readily available. The patient 
underwent hepatocyte microbead transplantation 12 days after admission; (40ml of infusate 
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containing 3 x107/kg neonatal cells (first infusion) and 2.25x107/kg neonatal cells (second infusion) 
which was tolerated well without any adverse effects. This patient survived for a further 31 days with 
supportive management at which time a suitable organ became available and she underwent LT. 
Microbeads were washed out at time of the LT. Adhesions were not noted at laparotomy. She is well 
now 2.5 years post-transplant.  
Child 2 presented with coagulopathy (INR of 7) and encephalopathy at the age of 18 months. He was 
listed for liver transplantation but as no organ became immediately available he underwent microbead 
transplantation as a bridging intervention day 2 of admission. The patient received a total of 
1.7x107/kg neonatal hepatocytes and made a full recovery with a normal INR 10 days post microbead 
transplantation and he did not suffer any adverse events. Microbeads were washed out 6 months post 
infusion at which time some fibrous bands between clumps of cells and the omentum were described 
at laparoscopy. Nine months later he presented with an INR of 17 and encephalopathy at which time 
he was listed once again for LT and received an organ shortly after listing. At time of LT, clumps of 
microbeads were retrieved but adhesions were not observed and the child remains well 6 months post 
liver transplantation.  
Child 3 was diagnosed with a rare inborn error of sulphite metabolism, which is associated with 
irreversible neurological damage and early death. The patient underwent intraportal infusion of a total 
6.6 x 108 cryopreserved hepatocytes over 4 infusion, with the first transplantation on day 2 of life. 
Biochemical stability was achieved, with sulphite and urinary s-sulfocysteine lower than expected, 
given previous experience with infants suffering this condition, though it is not possible to draw firm 
conclusions regarding the efficacy of hepatocyte transplantation from the improvement in 
biochemical parameter alone.   
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Discussion  
We suggest that neonatal livers, currently not used for organ transplant may be an ideal cell source for 
hepatocyte transplantation. Neonatal hepatocytes have high viability, attachment efficiency and 
metabolic function post-cryopreservation and may be a suitable alternative to adult hepatocytes. 
Results from the Chandler loop model suggest neonatal hepatocytes may not activate coagulation to 
the same extent as adult hepatocytes and may express less TF. In a small sample of patients, neonatal 
hepatocytes were shown to be suitable for clinical hepatocyte transplantation, with no patients 
showing adverse effects.  
The ability to cryopreserve hepatocytes is essential so they can be stored until needed for emergency 
treatment. This is one of the major advantages of hepatocyte transplantation versus LT. However, the 
cryopreservation process adversely affects viability, function and attachment efficiency of 
hepatocytes, with LDH leakage significantly increased upon thawing (15). Hepatocytes derived from 
neonatal hepatocytes are able to withstand the cryopreservation and thawing process significantly 
better than adult hepatocytes, with significantly greater viability and less LDH leakage. Further 
research is required into the molecular membrane structure of neonatal and adult hepatocytes and how 
this may affect cryopreservation. The use of neonatal hepatocytes that have high viability post 
thawing has the potential to increase the stock of good quality hepatocytes used for off-the-shelf 
emergency hepatocyte transplantation.  
Fully functional neonatal hepatocytes are vital to the success of hepatocyte transplantation to provide 
sufficient enzyme function to rescue the enzyme deficient recipient. However, theoretical concerns 
have arisen about the functional maturity of neonatal cells. Newborn liver function is still in 
development during the early post-natal period and there is a decreased ability of the neonatal liver to 
metabolize and detoxify xenobiotic substances (16). We have shown albumin, alpha-1 antitrypsin, 
factor VII synthesis and ammonia metabolism in neonatal hepatocytes is comparable to adult 
hepatocytes, suggesting neonatal hepatocytes are functionally suitable for transplantation. Studies into 
the development of hepatic drug metabolizing enzymes have found that each enzyme system has its 
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own pattern of development (17). CYP3A7 is the primary isoform expressed in the neonatal period 
and declines rapidly after birth, with CYP3A4 taking over its function within the first few weeks of 
life. We found 4 out of 5 of the neonatal cells tested still had inducible CYP3A7 and CYP3A4 
activity. The expression of CYP1A2 is the last enzyme to develop, only present by 1 to 2 months of 
life (17). This is reflected by our results, with very low levels of CYP1A2 induction in 3 out of 5 
neonatal cells. Higher levels of induction in some neonatal cells may be related to drugs received 
prior or shortly after birth, including phenobarbital and midazolam. Quantitative data into the 
development of the phase II enzymes is limited but it has been suggested that the UGT enzymes, 
which metabolize 15% of all drugs, are triggered at birth and reach adult levels by 3 months (17). This 
suggests neonatal hepatocytes should have functioning phase II enzymes which is reflected in our 
results that show resorufin conjugation and UGT substrate consumption was similar to adult cells.   
In animal models, up to a 6-fold loss of hepatocytes has been observed within the first 24 hours of cell 
transplantation, with studies relating this early cell loss to activation of coagulation and complement 
cascades described as the instant blood mediated inflammatory reaction (IBMIR) (13,18–20). The 
IBMIR is triggered by the expression of tissue factor on the donor hepatocytes (21).  Neonatal cells 
may potentially be less thrombotic and immunogenic than adult liver derived cells allowing increased 
engraftment and function. Initial results using the Chandler loop model suggest neonatal hepatocytes 
do not cause platelet consumption and circulating white cell loss to the same extent as adult 
hepatocyte. There is some variability in the platelet counts of blood samples containing neonatal 
hepatocytes compared to adult hepatocytes, which may be related to the age of the donor. One of the 
donors used in this experiment was aged 4 days whereas the other two were aged 6 weeks and 7 
weeks respectively. Further experiments are required to determine if lower immunogenicity is 
observed within the first few days of life. Significant differences have been described between 
neonatal and adult coagulation systems with concentrations of vitamin K dependent factors II, VII, IX 
and X and contact factors XI and XII reduced to about 50% of normal adult values (22–24). 
Furthermore, activated partial thromboplastin time is prolonged in healthy full-term infants compared 
to adults (25). We found tissue factor expression was decreased in neonatal hepatocytes compared to 
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adult cells, which may partly explain the decreased coagulation activation. Potentially, if neonatal 
cells do not activate coagulation to the same extent as adult hepatocytes, cells have a much better 
chance of cell survival, providing sustained function for children with metabolic liver disease, without 
the need for multiple infusions.  
Previous work published on neonatal hepatocytes considered warm and cold ischaemic times a major 
limiting factor in isolating good quality hepatocytes, with ideal cold ischaemic time being limited to 
2.5 hours and warm ischemia time not exceeding 30 minutes, based on previous in vitro studies (26–
28). However, we have shown cold ischemia times of up to 8 hours and warm ischemia times of up to 
84 minutes can still produce hepatocytes with a high viability and yield. It is possible neonatal organs 
are able to withstand longer periods of ischemia due to their high quality yet the mechanisms involved 
in this process remain to be found.  
Although we have characterized neonatal and adult hepatocyte viability and function in vitro, we have 
yet to prove their clinical efficacy. A larger patient cohort is required to validate the enzymatic 
function of these cells in a range of liver-based metabolic diseases.   
Conclusions  
The use of neonatal livers as a cell source for hepatocyte transplantation may significantly increase 
the number of high quality cells available for transplantation, with the advantage of excellent cell 
viability, function and potentially lower activation of the IBMIR of cells. Neonatal hepatocytes have 
been used in a clinical context and though proof of clinical efficacy is still elusive, non-invasive 
markers of immune activation were decreased with use of neonatal cells. This cell source may 
significantly improve the clinical outcomes of hepatocyte transplantation for paediatric ALF or in-
born errors of metabolism.  
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Figure Legends  
 
Tables  
Table 1. Donor details from neonatal livers used to isolate primary hepatocytes. *born at 23 weeks + 
5 days. DNDD=donation after neurological determination of death   
 Figures  
Figure 1 Viability, yield and attachment efficiency of human  hepatocytes isolated from neonatal 
and adult livers (A) Cell viability upon hepatocyte isolation, Neonatal N=14, Adult N=14 (B) Cell 
yield per gram of liver tissue, Neonatal N=14, Adult N=14  (C) Cell viability following 
cryopreservation and thawing, Neonatal N=9, Adult N=9 (D) Viability assessed by MTT assay, 
Neonatal N=9, Adult N=9 (E) Plasma membrane damage assessed via lactate dehydrogenase (LDH) 
release, N=5 (F) Cell attachment assessed by SRB assay, Neonatal N=6, Adult=6 (G) Cell 
morphology of neonatal (left) and adult hepatocytes (right) 24 hrs post plating on collagen coated 
plates *P<0.05, **<0.001 , ***P<0.001. Data represents mean±SEM 
Figure 2 Metabolic functions of neonatal and adult human hepatocytes (A) Albumin synthesis 
measured by ELISA N=8 (B) Alpha-1 antitrypsin synthesis measured by ELISA N=6 (C) Factor VII 
synthesis measured by ELISA N=3 (D) Ureagenesis measured using a quantichrome urea assay 
following incubation with 5mM ammonium chloride N=5 (E) Phase II activity measured by the 
metabolism of resorufin N=3 (F) Activity of UGT was measured by glucuronidated luciferin 
production following incubation with 50µM uridine 5’diphosphoglucuronic acid (UDPGA) and 
proluciferin substrates (50µM UGT multienzyme mix) N=3 N.S = not significant, P>0.05. Data 
represents mean±SEM.  
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Figure 3 Induction of cytochrome p450 enzymes in human neonatal and adult hepatocytes. 
Hepatocytes were cultured for 24h at 37°C, 5% CO2 and cytochrome metabolism induced every day 
for 3 days before detection of cytochrome activity (A) CYP1A2 activity in neonatal hepatocytes 
measured by Luciferin-ME following treatment with 50µM omeprazole (OMP) or DMSO control (B) 
CYP2C9 activity in neonatal hepatocytes measured by Luciferin-H following treatment with 1mM 
phenobarbital (PHE) or DMSO control (C) CYP2B6 activity in neonatal hepatocytes measured by 
Luciferin-2B6 following treatment with 1mM phenobarbital (PHE) or DMSO control (D) CYP3A4 
activity in neonatal hepatocytes measured by Luciferin-IPA following treatment with 25µM 
rifampicin (RIF) or DMSO control (E) CYP3A7 activity in neonatal hepatocytes measured by 
Luciferin-PFBE following treatment with 25µM  rifampicin (RIF) or DMSO control. (F) Cytochrome 
P450-1A1/1A2 activity in neonatal and adult hepatocytes was assessed by measuring the conversion 
of 7-ethoxyresorufin to resorufin following induction with 50µM omeprazole or DMSO controls for 3 
days.  
Figure 4 Coagulation and complement activity in ABO-matched blood following incubation 
with neonatal and adult human hepatocytes in the Chandler loop model (A) Platelet count (B) 
White cell count (C) C5b-9 expression N=3 (D) Chandler loop design PVC tubing 
(3/16”x1x16”x40cm) was filled with 6mls ABO matched blood and hepatocytes. Loops were closed 
into circuits with heparin coated 3/16” polystyrene connectors. Tubing loops were rotated at 24rpm 
and incubated at 37°C for 0, 15, 30 and 60 minutes. (E) RNA was extracted from neonatal and adult 
hepatocyte lysates. qPCR analysis for the tissue factor gene was carried out using Applied Biosystems 
QuantStudio 7 Flex Real Time PCR system (Thermo Fisher Scientific, Paisley, UK). Results are 
normalised to expression of the housekeeping gene β-actin. N=5, ***P<0.001. (F) Tissue Factor 
expression in hepatocytes isolated from adult and neonatal livers. Cryopreserved hepatocytes were 
thawed, plated in chamber slides overnight at 37°C, 5% CO2 and stained with a rabbit monoclonal 
tissue factor antibody. (A) Tissue factor expression (B) DAPI. 
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